FDA approves Boehringer Ingelheim's Semintra for feline hypertensionOctober 2, 2018The U.S. Food & Drug Administration has approved Semintra (telmisartan oral solution) 10 mg/mL oral solution for the control of systemic hypertension in cats, according to Boehringer Ingelheim. The product was designed specifically with cats in mind to provide safe, reliable, and convenient long-term control of blood pressure, said Boehringer Ingelheim. "We are proud to continue to set new standards of care for cats to optimize their health and well-being through the veterinarian," said Shawn Hooker, global head of Strategic Business Unit Pet Vet at Boehringer Ingelheim. "Early disease detection and early treatment are key to ensure cats live longer and happier lives. With Semintra, we offer a pet owner-friendly, easy-to-give solution to help raise the quality of life of cats with hypertension, while providing reliable long-term blood pressure control." Semintra is for oral use in cats only. The most common side effects reported in field studies include vomiting, diarrhea, lethargy, anemia, dehydration, poor appetite, and weight loss. It has not been evaluated in cats with systolic blood pressure > 200 mmHg, cats with hepatic disease, cats younger than 9 months of age, or cats that are pregnant, lactating, or intended for breeding. Visit semintra.com for …
SPONSORED CONTENTThe Case for Year-Round Heartworm Prevention and Affordable OptionsVeterinarians are often more than just clinicians - they’re advisors, educators, and, increasingly, financial counselors. In today’s economy, pet owners may hesitate to invest in year-round prevention due to budget constraints; but, skipping even a few months of heartworm protection can have serious consequences. + Learn More
